TLR2 and colorectal cancer: In addition, recent pre-clinical work using CAR-T cells containing an anti-CD318 single-chain variable fragment (anti-CD318 scFv), CD3ζ, CD28, and Toll-like receptor 2 (TLR2) domains, shows great promise as a novel strategy for the treatment of colorectal cancer (86).